Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
284.2 SEK | +1.00% |
|
+2.82% | +6.44% |
Jun. 19 | Sobi Wins EU Approval for Hemophilia A Drug Altuvoct | MT |
Jun. 19 | European Commission Grants Sobi® Marketing Authorisation for Altuvoct? for Treatment of Haemophilia A | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.44% | 9.05B | |
+2.97% | 94.74B | |
-3.68% | 37.28B | |
-11.61% | 32.68B | |
+74.21% | 27.72B | |
-13.40% | 16.19B | |
-2.29% | 13.88B | |
-12.21% | 11.58B | |
+188.83% | 10.92B | |
-53.94% | 9.54B |
- Stock Market
- Equities
- SOBI Stock
- News Swedish Orphan Biovitrum AB
- Swedish Orphan Biovitrum : Sobi, Apellis Blood Disease Drug Shown Better Than Standard of Care in Study